Promethera Biosciences, a Belgian biotechnology company developing therapies for liver disease, says Eric Halioua has resigned as CEO of Promethera.
He has decided to leave in order to concentrate on other projects, the company said.
Halioua has been CEO of the company since it was founded in 2009 and was the driving force behind its operational and financial growth, working closely with Professor Etienne Sokal, the company’s scientific founder.
The search for his successor has begun and Chairman John Tchelingerian will assume the role of acting CEO during the transition.
‘On behalf of the board of directors and the company as a whole, we would like to extend our heartfelt thanks to Eric for his contribution to the successful growth of Promethera Biosciences since it was first established. We wish him all the very best in his plans for the future,’ said Tchelingerian.
In addition to treatments for liver disease, Promethera is also developing two products based on human liver progenitor cells: Promethera HepaStem, a cell therapy product; and Promethera H2Screen/H3Screen, a non-therapeutic in vitro product, based on a recently discovered and patented liver progenitor cell type.
Promethera Biosciences is a spin-off from the Université Catholique de Louvain (UCL) in Belgium.
